R. P. PHARIS and D. M. REID The idea of a separate Encydopedia volume dealing with the "interrelations of plant hormones with factors in the environment of the plant, and its organs and tissues" originated with N. P. KEFFORD, and we are most appreciative of the help and advice provided by Prof. KEFFORD in the formative stages of this volume. We have thus interpreted "environment" very broadly to indude not only factors external to the plant, e. g. , gravity, light, temperature, wind, mechanieal wounding, water, organism s (induding pollen), and magnetic and electric stimuli, but internaI factors as well (e. g. , nutrients, both inorganic and photoassimilate, direction, and time). In our definition of "hormonaI effect", or "hormonaI involvement", we have asked our authors to take a broad ap proach, and to examine not only phenomena that are mediated by the known plant hormones, but to discuss as well a wide variety of processes and events where hormonal involvement is implied through more indirect analyses and observations. The volume begins with environmental factors internaI to the plant; R. J. WEAVER and J. O. JOHNSON thus examine "hormones and nutrients", their inter relationship in movement, accumulation, and diversion. As one studies a plant during its rapid growth phase, and later as maturation and aging proceed, it becomes apparent that time is an environmental cue of great significance, one which may exert a major influence via hormonal messages.

Designed to be a practical handbook on clinical trial management in these key therapeutic areas, 'Clinical Trials in Rheumatoid Arthritis and Osteoarthritis' is aimed at principal investigators pharmaceutical physicians and other pharmaceutical staff involved in the design, conduct and monitoring of these increasingly complex diseases. In the last several years a new classes of biologic agents have emerged and changed the treatment paradigm for patients, not only with classically defined rheumatoid arthritis, but also with other related diseases such as ankylosing spondylitis and psoriatic arthritis. Furthermore, osteoarthritis is a major disease state that is often treated by the rheumatologist, but is one where patient management programs are currently limited with a need for new therapeutic approaches. In both inflammatory and non-inflammatory arthritic conditions, clinical trials have become both large and complex due to the nature of the diseases, with ever-challenging new surrogate end-points being employed. Topics covered in this title will therefore include study design, clinical endpoints, technical issues, data collection, use of centralized medical image reading facilities and biochemical marker laboratories, as well as data analysis and future therapies. This book takes the user through the process step-by-step from start to finish, also providing a background on the regulatory guidelines, ethical implications, endpoints, and current therapies.

Osteoporosis affects an estimated 3 million people in the UK. The condition causes the bones to become more fragile and therefore more prone to fractures, along with pain, a loss of movement, and an inability to perform daily tasks. One in two women and one in five men in the UK will suffer a fracture after the age of 50.
Aimed at patients and carers, this book covers topics such as who is affected, what the risk factors are, and how patients can prevent or lessen the efefcts. The book looks forward to advances in diagnosis and treatment and how they have improved health outcomes of patients. Written by a leading osteoporosis specialist and Scientific Advisory Committee Member of the National Osteoporosis Society, this addition to the Facts series is a comprehensive guide to understanding and coping with this debilitating disease.